Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

被引：78

作者：

Cilloni, Daniela ^{[1
]}

Messa, Francesca ^{[1
]}

Arruga, Francesca ^{[1
]}

Defilippi, Ilaria ^{[1
]}

Gottardi, Enrico ^{[1
]}

Fava, Milena ^{[1
]}

Carturan, Sonia ^{[1
]}

Catalano, Renata ^{[1
]}

Bracco, Enrico ^{[1
]}

Messa, Emanuela ^{[1
]}

Nicoli, Paolo ^{[1
]}

Diverio, Daniela ^{[2
]}

Sanz, Miguel A. ^{[3
]}

Martinelli, Giovanni ^{[4
]}

Lo-Coco, Francesco ^{[5
]}

Saglio, Giuseppe ^{[1
]}

机构：

[1] Univ Turin, Dept Clin & Biol Sci, Turin, Italy

[2] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[3] Hosp Univ La Fe, Dept Med Biopathol, Valencia, Spain

[4] Univ Bologna, Seragnoli Inst, Dept Hematol, Bologna, Italy

[5] Univ Tor Vergata, Dept Biopathol, Rome, Italy

来源：

HAEMATOLOGICA | 2008年 / 93卷 / 06期

关键词：

WT1; minimal residual disease; acute leukemia; RQ-PCR;

D O I：

10.3324/haematol.12165

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The Wilms' tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients. The study was designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of patients at high risk of relapse. A prospective study based on a quantitative Real-Time PCR (TagMan) assay in 562 peripheral blood samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established.The evaluation of WT1 in peripheral blood samples after induction chemotherapy can distinguish the continuous complete remission patients from those who obtain only an "apparent" complete remission and who could relapse within a few months. WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified.

引用

页码：921 / 924

页数：4

共 24 条

[1]

Baird PN, 1997, EXP HEMATOL, V25, P312

[2]

Barragán E, 2004, HAEMATOLOGICA, V89, P926

[3] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[4] WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome [J].

Cilloni, D ;

Saglio, G .

ACTA HAEMATOLOGICA, 2004, 112 (1-2) :79-84

[5] Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System score in patients with myelodysplastic syndromes [J].

Cilloni, D ;

Gottardi, E ;

Messa, F ;

Fava, M ;

Scaravaglio, P ;

Bertini, M ;

Girotto, M ;

Marinone, C ;

Ferrero, D ;

Gallamini, A ;

Levis, A ;

Saglio, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1988-1995

[6] Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients [J].

Cilloni, D ;

Gottardi, E ;

De Micheli, D ;

Serra, A ;

Volpe, G ;

Messa, F ;

Rege-Cambrin, G ;

Guerrasio, A ;

Divona, M ;

Lo Coco, F ;

Saglio, G .

LEUKEMIA, 2002, 16 (10) :2115-2121

[7]

Cilloni D, 2006, METH MOLEC MED, V125, P199

[8]

Gaiger A, 1999, EUR J HAEMATOL, V63, P86

[9] Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia [J].

Gaiger, A ;

Schmid, D ;

Heinze, G ;

Linnerth, B ;

Greinix, H ;

Kalhs, P ;

Tisljar, K ;

Priglinger, S ;

Laczika, K ;

Mitterbauer, M ;

Novak, M ;

Mitterbauer, G ;

Mannhalter, C ;

Haas, OA ;

Lechner, K ;

Jäger, U .

LEUKEMIA, 1998, 12 (12) :1886-1894

[10] Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts [J].

Guerrasio, A ;

Pilatrino, C ;

De Micheli, D ;

Cilloni, D ;

Serra, A ;

Gottardi, E ;

Parziale, A ;

Marmont, F ;

Diverio, D ;

Divona, M ;

Lo Coco, F ;

Saglio, G .

LEUKEMIA, 2002, 16 (06) :1176-1181

← 1 2 3 →